Ecopipam is a first-in-class investigational small-molecule therapy that selectively blocks dopamine-1 (D1) receptors. It is not an antipsychotic. This mechanism differs from currently approved ...

Sealed inside a steel tube at crushing depth, breathing manufactured air, eating off the same table where surgery will be performed if something goes wrong, India's submariners inhabit one of Earth's ...

MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...

To meet LSA’s natural science requirement, most students select two of these courses and exert the minimum effort needed to acquire an A — which could be a problem because most feel they’re learning ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND ...

A graduate of the University of Ibadan inspires many as she shares what she did in 300‑level that made her finish from the ...

NYC is planning upgrades to enhance the 14th Street busway with improvements for pedestrians, cyclists, and transit riders ...

The numbers don’t make for pretty reading. Between 2011 and 2021, the number of students studying English literature at ...

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...